AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study
المؤلفون الرئيسيون: | Dummer, R, Robert, C, Chapman, P, Sosman, J, Middleton, M, Bastholt, L, Kemsley, K, Cantarini, M, Morris, C, Kirkwood, J |
---|---|
التنسيق: | Journal article |
منشور في: |
2008
|
مواد مشابهة
-
DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
حسب: Gupta, A, وآخرون
منشور في: (2013) -
Author Correction: Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer
حسب: Jin-Hang Gao, وآخرون
منشور في: (2022-03-01) -
MEK1/2 blockade by AZD6244 (ARRY-142886) inhibits tumor growth and progression in an orthotopic human lung adenocarcinoma model with enhanced efficacy when combined with cediranib
حسب: Takahashi, O, وآخرون
منشور في: (2009) -
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
حسب: Kirkwood, J, وآخرون
منشور في: (2012) -
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
حسب: Leijen, S, وآخرون
منشور في: (2011)